Moderna receives Health Canada approval for RSV vaccine for adults aged 60 years and older

8 November 2024 - mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only ...

Read more →

Canada's Drug Agency recommends Winrevair (sotatercept) for reimbursement

8 November 2024 - Merck announced that Canada's Drug Agency has recommended Winrevair (sotatercept) for reimbursement in combination with standard ...

Read more →

Expanded age indication for GSK's Arexvy, the first respiratory syncytial virus vaccine approved in Canada for adults aged 50-59 at increased risk

5 November 2024 - Clinical development program continues to evaluate safety and immunogenicity in adults aged 18-49 at increased risk ...

Read more →

NS parents dismayed by lack of access to new RSV vaccines for infants

3 November 2024 - Officials say there is no universally available, publicly funded RSV vaccine program for newborns in Nova Scotia. ...

Read more →

Differences in drug shortages in the US and Canada

31 October 2024 - In this cross-sectional study, there were 104 reports of drug-related supply chain issues that occurred from 2017 ...

Read more →

Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Verzenio (abemaciclib) in expanded early breast cancer indication

29 October 2024 - Eli Lilly Canada is pleased to announce that it received a positive Canada's Drug Agency (CDA-AMC, formally ...

Read more →

Breast Cancer Canada 'Progress Report' reveals major gaps in screening and treatment delays across Canada

28 October 2024 - Breast Cancer Canada has released the 2024 Progress Report on Breast Cancer in Canada.  ...

Read more →

Canada’s Drug Agency announces recipients of funding to enhance rare disease registries

21 October 2024 - Canada’s Drug Agency is pleased to announce the successful applicants from our 2024 Request for Proposals (RFP) ...

Read more →

Health Canada approves first and only oral targeted treatment for brain cancer

22 October 2024 - Pivotal Phase 3 study shows significant improvement in progression-free survival with a favourable safety profile. ...

Read more →

Nine provinces approve accelerated public reimbursement of diffuse large B-cell lymphoma treatment under new early access process

21 October 2024 - AbbVie today announced that nine provinces have provided accelerated public coverage of Epkinly. ...

Read more →

Arcutis announces Health Canada approval of Zoryve (roflumilast) foam 0.3% to treat seborrheic dermatitis in individuals 9 years of age and older

18 October 2024 - Zoryve foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved ...

Read more →

Fresenius Kabi launches Tyenne, the first and only approved tocilizumab biosimilar in Canada

17 October 2024 - Tyenne is the first and only tocilizumab biosimilar to be launched in Canada. ...

Read more →

Government of Canada announces new appointment to the Patented Medicine Prices Review Board

17 October 2024 - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine ...

Read more →

Incyte announces Health Canada approval of Opzelura (ruxolitinib) cream for the treatment of atopic dermatitis and non-segmental vitiligo

16 October 2024 - First and only treatment approved by Health Canada for repigmentation of non-segmental vitiligo. ...

Read more →

Acadia Pharmaceuticals announces Health Canada approval of Daybue (trofinetide) for the treatment of Rett syndrome

16 October 2024 - Daybue is the first and only therapy approved in Canada for the treatment of Rett syndrome, a ...

Read more →